{
    "data": [
        {
            "id": "4565987",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-22T13:25:30-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/471173955/image_471173955.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Compelling Valuation Vs. Expensive Acquisitions",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103219",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "427405",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4565987-viatris-compelling-valuation-vs-expensive-acquisitions"
            }
        },
        {
            "id": "4564250",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-13T15:31:44-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1369076493/image_1369076493.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Oyster Point Pharma: Interesting Opportunity To Acquire Undervalued CVR",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425736",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4564250-oyster-point-pharma-interesting-opportunity-to-acquire-undervalued-cvr"
            }
        },
        {
            "id": "4558673",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-17T08:27:28-05:00",
                "isLockedPro": false,
                "commentCount": 73,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181272310/image_1181272310.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris And Oyster Point: Mylan All Over Again?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "437655",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4558673-viatris-and-oyster-point-mylan-all-over-again"
            }
        },
        {
            "id": "4555363",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-09T11:28:03-05:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351826681/image_1351826681.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: A Spinoff That Got Even More Interesting",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106648",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "419274",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4555363-viatris-spinoff-more-interesting"
            }
        },
        {
            "id": "4551197",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-31T15:52:18-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/3093806/image_3093806.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris Ahead Of Q3 Earnings: Regrets? I've Had A Few",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "417649",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4551197-viatris-ahead-of-q3-earnings-regrets-ive-had-a-few"
            }
        },
        {
            "id": "4550888",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-30T08:21:06-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1158411792/image_1158411792.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris Asset Disposals Make The Value Case For Their Branded Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105192",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "417397",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4550888-viatris-asset-disposals-value-case-for-branded-portfolio"
            }
        },
        {
            "id": "4542995",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-25T18:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399399726/image_1399399726.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Take These Broken Wings And Learn To Fly Again Viatris",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103219",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "410960",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4542995-viatris-broken-wings"
            }
        },
        {
            "id": "4539042",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-05T22:36:21-04:00",
                "isLockedPro": false,
                "commentCount": 122,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344251576/image_1344251576.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: 5% Dividend Yield Is A Threat For Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "407653",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4539042-viatris-stock-5-percent-dividend-yield-threat-investors"
            }
        },
        {
            "id": "4535910",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-20T03:28:19-04:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1313998462/image_1313998462.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Products, Profitability And Pipeline - The Keys To Success",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "388648",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4535910-viatris-products-profitability-pipeline-keys-success"
            }
        },
        {
            "id": "4532961",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-11T11:00:02-04:00",
                "isLockedPro": false,
                "commentCount": 95,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314035412/image_1314035412.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: FX-Related Fears Overblown, Optimizations Bear Fruit",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "387222",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4532961-viatris-fx-related-fears-overblown-optimizations-bear-fruit"
            }
        },
        {
            "id": "4528410",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-01T22:40:49-04:00",
                "isLockedPro": false,
                "commentCount": 81,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322464926/image_1322464926.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: A Spinoff To Own",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106648",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "385186",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4528410-viatris-a-spin-off-to-own"
            }
        },
        {
            "id": "4523638",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-15T15:01:52-04:00",
                "isLockedPro": false,
                "commentCount": 100,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1343466961/image_1343466961.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Guidance Likely To Be Cut With Q2 Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103219",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "382877",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4523638-viatris-guidance-likely-to-be-cut-with-q2-results"
            }
        },
        {
            "id": "4521160",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-30T10:23:35-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320218178/image_1320218178.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Oyster Therapeutics: State Of Business Is Confounding",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "380687",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4521160-oyster-therapeutics-state-of-business-is-confounding"
            }
        },
        {
            "id": "4519244",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-19T21:23:26-04:00",
                "isLockedPro": false,
                "commentCount": 65,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310985956/image_1310985956.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Organon Vs. Viatris: Who Is The Clear Winner?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "379030",
                            "type": "sentiment"
                        },
                        {
                            "id": "379031",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4519244-organon-vs-viatris-stock-who-clear-winner"
            }
        },
        {
            "id": "4508988",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-09T09:42:34-04:00",
                "isLockedPro": false,
                "commentCount": 41,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/862433964/image_862433964.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: A Cigar Butt With Many Puffs Left",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "373191",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4508988-viatris-a-cigar-butt-with-many-puffs-left"
            }
        },
        {
            "id": "4508982",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-09T09:14:33-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/641885492/image_641885492.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: The Market Is Not Buying It - Downtrend Since 2015",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "373029",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4508982-viatris-the-market-is-not-buying-it-downtrend-since-2015"
            }
        },
        {
            "id": "4502452",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-20T14:54:56-04:00",
                "isLockedPro": false,
                "commentCount": 127,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1208763539/image_1208763539.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: 3 Things That Can Break The Bull Thesis In 2022",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103219",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "370552",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4502452-viatris-3-things-that-can-break-the-bull-thesis-in-2022"
            }
        },
        {
            "id": "4500998",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-12T12:05:08-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1301045569/image_1301045569.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris Showed True Colors With Biosimilar Division Sale, Still Good Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "369454",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4500998-viatris-showed-true-colors-with-biosimilar-division-sale-still-good-value"
            }
        },
        {
            "id": "4500434",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-08T09:12:25-04:00",
                "isLockedPro": false,
                "commentCount": 107,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1300036753/image_1300036753.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "I No Longer Think Viatris Is A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "368897",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4500434-i-no-longer-think-viatris-is-a-buy"
            }
        },
        {
            "id": "4494630",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-10T18:36:55-05:00",
                "isLockedPro": false,
                "commentCount": 79,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/481308294/image_481308294.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Takeaways From Management At The Raymond James Conference",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85376",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "365043",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4494630-viatris-takeaways-from-management-at-the-raymond-james-conference"
            }
        },
        {
            "id": "4493128",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-05T00:53:21-05:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458662085/image_458662085.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Confusion Reigns, 3 Questions To Management",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85376",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "363967",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4493128-viatris-confusion-reigns-3-questions-to-management"
            }
        },
        {
            "id": "4491714",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-01T11:21:36-05:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303850380/image_1303850380.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris Stock: Why So Serious? Let's Put A Buy On Your Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "363722",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4491714-vtrs-stock-put-a-buy-on-your-portfolio"
            }
        },
        {
            "id": "4491399",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-28T13:36:00-05:00",
                "isLockedPro": false,
                "commentCount": 121,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/137374746/image_137374746.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Perhaps An Overreaction",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103219",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "363592",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4491399-viatris-q4-earnings-stock-dives"
            }
        },
        {
            "id": "4491308",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-28T10:09:02-05:00",
                "isLockedPro": false,
                "commentCount": 113,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291142737/image_1291142737.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "My Investment Thesis On Viatris Remains Intact After The Sale Of The Biosimilars Assets",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "363575",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4491308-my-investment-thesis-on-viatris-remains-intact"
            }
        },
        {
            "id": "4488565",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-19T05:57:19-05:00",
                "isLockedPro": false,
                "commentCount": 86,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1083005864/image_1083005864.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris Vs. Organon: Surprisingly Undervalued, But Which Is The Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "362225",
                            "type": "sentiment"
                        },
                        {
                            "id": "362226",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4488565-viatris-vs-organon-which-is-the-better-buy"
            }
        },
        {
            "id": "4480468",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-20T01:47:00-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292355769/image_1292355769.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Cheap Stock, Solid Dividend Yield, And Impressive Free Cash Flow",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103576",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "357812",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4480468-viatris-cheap-stock-solid-dividend-yield-and-impressive-free-cash-flow"
            }
        },
        {
            "id": "4479140",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-11T17:43:00-05:00",
                "isLockedPro": false,
                "commentCount": 86,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1333810802/image_1333810802.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Prepare For Takeoff",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356705",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4479140-viatris-prepare-for-takeoff"
            }
        }
    ]
}